產(chǎn)品分類(lèi)導(dǎo)航
2025制藥工業(yè)深圳展
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control

Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control

更新時(shí)間:2025-06-20

價(jià)格:  元/個(gè)
CAS號(hào): 2381089-83-2
藥典: 中國(guó)藥典,企業(yè)標(biāo)準(zhǔn)
級(jí)別: injection
立即詢盤(pán)
收藏
產(chǎn)品詳情
產(chǎn)品關(guān)鍵詞: Triple-Action Agonist,Type 2 Diabetes and Weight Management,GIP/GLP-1/GCG Receptor Activation,Once-Weekly Dosing,Innovative Obesity Therapy
是否為生產(chǎn)商:
產(chǎn)品包裝規(guī)格: 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 10Ampoules/Box
主要銷(xiāo)售市場(chǎng): 中國(guó),北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產(chǎn)品描述:


Mechanism of Action

Retatrutide is a triple-agonist peptide that simultaneously activates three key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This unique mechanism provides comprehensive metabolic benefits:

  1. GLP-1 Receptor Activation:Enhances glucose-dependent insulin secretion, improving postprandial glucose control.Slows gastric emptying, promoting satiety and reducing food intake.Suppresses glucagon secretion, further aiding in glucose regulation.
  2. GIP Receptor Activation:Stimulates insulin secretion in a glucose-dependent manner, enhancing insulin sensitivity.Contributes to fat metabolism and preservation of β-cell function.
  3. Glucagon Receptor Activation:Increases energy expenditure through hepatic glucose output and lipid mobilization.Promotes fatty acid oxidation and thermogenesis, supporting weight reduction.
  4. The combination of these actions results in a synergistic effect that enhances weight loss, improves glycemic control, and optimizes overall metabolic health.

Applications

  1. Type 2 Diabetes Management: Retatrutide helps regulate blood glucose levels and improve glycemic control.
  2. Weight Management: It has demonstrated significant weight loss benefits, making it suitable for obesity management.
  3. Non-Alcoholic Fatty Liver Disease (NAFLD): Retatrutide has shown potential in reducing liver fat content.
  4. Metabolic Syndrome: It addresses multiple aspects of metabolic dysfunction, including lipid metabolism and energy expenditure.

Dosage Instructions

  1. Initial Dose: The starting dose is typically 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 10 mg, or higher, depending on individual response and tolerability.
  3. Injection Instructions: Administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
上海浦津林州制藥有限公司
注冊(cè)資本
聯(lián)系人
聯(lián)系電話
查看聯(lián)系方式
快速詢盤(pán)
詢盤(pán)主題
請(qǐng)輸入詢盤(pán)主題
詢盤(pán)信息
請(qǐng)輸入詢盤(pán)信息
滑動(dòng)驗(yàn)證
請(qǐng)完成滑塊驗(yàn)證
快速發(fā)送詢盤(pán)
CPHI制藥在線為您找到Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control 價(jià)格、Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control 詳細(xì)參數(shù)、Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control 相關(guān)產(chǎn)品、Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control 供應(yīng)商等信息,想了解當(dāng)前Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control 最新報(bào)價(jià),請(qǐng)聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國(guó)際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號(hào)-57